Table 1.
Baseline information of PD patients enrolled in gait analyses.
| PD - CCPS (n=21) | PD + CCPS (n=16) | p value | |
|---|---|---|---|
| Age (y) | 64.7±4.5 | 69.0±8.4 | 0.079a |
| Sex (female/male, n) | 11/10 | 8/8 | 0.886b |
| BMI (kg/m2) | 23.3±3.7 | 23.9±3.1 | 0.616a |
| Education (y) | 10.2±3.2 | 10.6±4.2 | 0.762a |
| Disease duration (y) | 5.4±4.4 | 7.3±4.5 | 0.226a |
| Hoehn-Yahr stage | 2.0(1.0, 2.0) | 2.5(1.6, 3.0) | 0.006c |
| LEDD (mg) | 405.64±353.76d | 724.10±276.66 | 0.006a |
| MDS-UPDRS III | 29.0±12.2 | 39.4±12.3 | 0.023a |
| MMSE | 28.0(24.5, 28.5) | 27.0(26.0, 28.0) | 0.844c |
| MoCA | 22.7±3.9 | 22.2±5.4 | 0.757a |
PD: Parkinson’s disease; CC: camptocormia; PS: Pisa syndrome; PD - CCPS: PD without CC or PS group; PD + CCPS: PD with CC or PS group; BMI: body mass index; LEDD: levodopa equal daily dose; MDS-UPDRS: Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment. The values are expressed as the mean ± SD for normally distributed continuous variables, mean (interquartile range) for abnormally distributed continuous variables, and number for categorical variables.
a
Independent samples t-test;
b
Crosstabs;
c
Mann-Whitney test.
d
Data were unavailable for 1 patient. p<0.05 is considered statistically significant.